On April 6, 2016 Arrowhead Research Corporation (NASDAQ:ARWR) reported that it has changed its corporate name to Arrowhead Pharmaceuticals, Inc (Press release, Arrowhead Research Corporation, APR 6, 2016, View Source [SID:1234510482]). The company’s common stock will continue to trade on the NASDAQ Global Select Market under the existing stock ticker symbol, ARWR. These shares have been assigned a new CUSIP number of 04280A100. Holders of stock certificates with the prior corporate name, need not take any action. Schedule your 30 min Free 1stOncology Demo! As part of this name change, the company has also launched a new corporate website at www.arrowheadpharma.com and a new Twitter handle @ArrowheadPharma.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Chris Anzalone, Ph.D., president and CEO of Arrowhead Pharmaceuticals, said: "Now is the time to acknowledge that our key priorities are increasingly focused on advancing products through clinical development to bring innovative new medicines to patients. The name Arrowhead Pharmaceuticals is more consistent with our stage of development as a company and reflects the great progress we’re making on our broad pipeline of RNAi-based drugs."